CNS tumor type prevalence according to age group: an analysis of 21,000 cases confirmed by methylation profiling, with a focus on adolescents and young adults
BACKGROUND: Approximately 12,000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population. METHODS: We assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA and adult). RESULTS: The cohort of 21,712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (e.g. medulloblastoma) as well as those common in older adults (e.g. glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions. CONCLUSION: Large-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.
Authors
- Adriana Fonseca (ORCID: https://orcid.org/0000-0002-6382-6833)
- Mark Raffeld (ORCID: https://orcid.org/0000-0002-4039-6957)
- Cristiane M. Ida (ORCID: https://orcid.org/0000-0003-2768-2913)
- Christopher H. Dampier (ORCID: https://orcid.org/0000-0003-3099-6462)
- Leeor Yefet
- Zied Abdullaev (ORCID: https://orcid.org/0000-0001-6345-2088)
- Karen Dazelle
- Jeffrey Gagan (ORCID: https://orcid.org/0000-0003-4676-9969)
- Hye‐Jung Chung
- Julie Bennett
- Pieter Wesseling
- Dipak Poria
- MacLean Nasrallah
- Pascale Varlet
- Omkar Singh
- Michelle Lam
- Patrick Y Wen
- Martha Quezado
- Martin van den Bent
- Ina Lee
- Kenneth Aldape
- Gelareh Zadeh
- Eric Bouffet
- Arnault Tauziède-Espariat
Institutions
- Mayo Clinic (US)
- Children's National (US)
- Harvard University (US)
- Inserm (FR)
- Hospital for Sick Children (CA)
- Princess Margaret Cancer Centre (CA)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Centre Hospitalier Sainte-Anne (FR)
- Mayo Clinic in Arizona (US)
- Princess Máxima Center (NL)
- Institut de Psychiatrie et Neurosciences de Paris (FR)
- National Cancer Institute (US)
- FHU Neurovasc (FR)
- Mayo Clinic in Florida (US)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2026-04-11
- DOI
- https://doi.org/10.1093/neuonc/noag082
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00